Kevan M. Shokat

54.8k citations

305 papers · 34.2k indexed · 13 hit papers · h-index 96

Molecular Biology top 0.05%
Oncology top 0.2%
Cell Biology top 0.05%
Immunology top 0.5%
Epidemiology top 0.5%

Co-authors: Zachary A. Knight J.M. OstremChao ZhangMartin L. Sos William A. Weiss Ulf Peters James A. Wells Neal Rosen
Topics: PI3K/AKT/mTOR signaling in cancer (68 papers)Protein Kinase Regulation and GTPase Signaling (46 papers)Monoclonal and Polyclonal Antibodies Research (26 papers)
Cited by: Molecular Biology Cell Biology Oncology
Journals: Nature Science Cell
Partner nations: United States United Kingdom Germany

In The Last Decade

Kevan M. Shokat

297 papers receiving 33.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

2013 1.7k citations J.M. Ostrem, Kevan M. Shokat et al. profile →
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

2010 1.3k citations Kevan M. Shokat et al. profile →
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response

2007 1.1k citations Jonathan H. Lin, Han Li et al. Science profile →
The translational landscape of mTOR signalling steers cancer initiation and metastasis

2012 978 citations Kevan M. Shokat, Davide Ruggero et al. profile →
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

2006 940 citations Zachary A. Knight, David Stokoe et al. profile →
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

2009 889 citations Zachary A. Knight, Davide Ruggero et al. profile →
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

2007 765 citations Jimmy A. Blair, Byron Hann et al. profile →
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR

2008 699 citations Zachary A. Knight, Kevan M. Shokat et al. Proceedings of the National Academy of Sciences profile →
Drugging the 'undruggable' cancer targets

2017 636 citations Kevan M. Shokat et al. profile →
Targeting the cancer kinome through polypharmacology

2010 541 citations Zachary A. Knight, Kevan M. Shokat et al. profile →
The unfolded protein response signals through high-order assembly of Ire1

2008 512 citations Chao Zhang, Kevan M. Shokat et al. profile →
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

2016 449 citations J.M. Ostrem, Kevan M. Shokat profile →
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells

2016 280 citations Kevan M. Shokat, Owen N. Witte et al. profile →

Peers

Countries citing papers authored by Kevan M. Shokat

Since Specialization

Citations

This map shows the geographic impact of Kevan M. Shokat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevan M. Shokat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevan M. Shokat more than expected).

Fields of papers citing papers by Kevan M. Shokat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevan M. Shokat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevan M. Shokat. The network helps show where Kevan M. Shokat may publish in the future.

Co-authorship network of co-authors of Kevan M. Shokat

This figure shows the co-authorship network connecting the top 25 collaborators of Kevan M. Shokat. A scholar is included among the top collaborators of Kevan M. Shokat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevan M. Shokat. Kevan M. Shokat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability 2022 ·Cancer Discovery ·Keelan Z. Guiley,Kevan M. Shokat	57
2	Tissue-restricted inhibition of mTOR using chemical genetics 2022 ·Proceedings of the National Academy of Sciences ·(unknown),(unknown),Leo J. Pallanck,Kevan M. Shokat	4
3	Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition 2019 ·Science Signaling ·Yoko Katsuno,Dominique S. Meyer,Ziyang Zhang,Kevan M. Shokat,Rosemary J. Akhurst,Kohei Miyazono,Rik Derynck	168
4	Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma 2019 ·Cancer Research ·Robyn A. Wong,(unknown),(unknown),Zhenyi An,Daphne A. Haas‐Kogan,Joanna J. Phillips,Kevan M. Shokat,William A. Weiss,Qi Fan	17
5	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors 2018 ·Molecular Cancer Therapeutics ·Chester E. Chamberlain,Michael S. German,Katherine Yang,Jason Wang,Henry F. VanBrocklin,(unknown),Kevan M. Shokat,Gregory S. Ducker,Grace Kim,Byron Hann,David B. Donner,Robert S. Warren,Alan P. Venook,Emily K. Bergsland,Danny Lee,Yucheng Wang,Eric K. Nakakura	34
6	INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC 2017 ·Molecular Cancer Research ·(unknown),Kevan M. Shokat	26
7	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin 2014 ·Proceedings of the National Academy of Sciences ·Ligong Chen,Yan Shu,Xiaomin Liang,Eugene C. Chen,Sook Wah Yee,Arik A. Zur,Shuanglian Li,Lu Xu,Kayvan R. Keshari,(unknown),Huan‐Chieh Chien,Youcai Zhang,Kari M. Morrissey,Jason Liu,J.M. Ostrem,Noah Younger,John Kurhanewicz,Kevan M. Shokat,Kaveh Ashrafi,Kathleen M. Giacomini	182
8	Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma 2014 ·Molecular Cancer Therapeutics ·(unknown),Dustin J. Maly,Yvan H. Chanthery,Daniel W. Sirkis,Jean L. Nakamura,Mitchel S. Berger,C. David James,Kevan M. Shokat,William A. Weiss,Anders I. Persson	23
9	Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers 2013 ·Proceedings of the National Academy of Sciences ·Michael Pourdehnad,Morgan Truitt,Imran Siddiqi,Gregory S. Ducker,Kevan M. Shokat,Davide Ruggero	204
10	Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide 2012 ·Cancer Research ·Miran Jang,Yeonghwan Kim,Hyeran Won,Sangbin Lim,(unknown),(unknown),Yoo Hong Min,(unknown),Kevan M. Shokat,Joohun Ha,Sung Soo Kim	25
11	Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers 2012 ·Cancer Discovery ·Krister J. Barkovich,Sujatmi Hariono,Adam L. Garske,Jie Zhang,Jimmy A. Blair,(unknown),Kevan M. Shokat,Theodore Nicolaides,William A. Weiss	39
12	Dose-Dependent Effects of Focal Fractionated Irradiation on Secondary Malignant Neoplasms in Nf1 Mutant Mice 2011 ·Cancer Research ·Jean L. Nakamura,(unknown),Emile Pinarbasi,Scott C. Kogan,Scott Vandenberg,Andrew Horvai,Bruce Faddegon,Dorothea Fiedler,Kevan M. Shokat,Benjamin T. Houseman,Richard C. Chao,Russell O. Pieper,Kevin Shannon	24
13	The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile 2011 ·Proceedings of the National Academy of Sciences ·(unknown),Gregory S. Ducker,Andrea J. Barczak,Rebecca Barbeau,David J. Erle,Kevan M. Shokat	90
14	Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers 2009 ·Clinical Cancer Research ·Ching Hang Wong,Frederick L. Baehner,Danislav S. Spassov,Deepika Ahuja,Donghui Wang,Byron Hann,Jimmy A. Blair,Kevan M. Shokat,Alana L. Welm,Mark M. Moasser	40
15	PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation 2008 ·Cancer Research ·Katsutoshi Oda,(unknown),Luika Timmerman,Pablo Rodriguez‐Viciana,David Stokoe,Keiko Shoji,Yuji Taketani,Hiroyuki Kuramoto,Zachary A. Knight,Kevan M. Shokat,Frank McCormick	136
16	IRE1 Signaling Affects Cell Fate During the Unfolded Protein Responsebreakdown → 2007 ·Science ·Jonathan H. Lin,Han Li,Douglas Yasumura,Hannah Cohen,Chao Zhang,Barbara Panning,Kevan M. Shokat,Matthew M. LaVail,Peter Walter	1140
17	A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN -Mutant Glioma 2007 ·Cancer Research ·Qi-Wen Fan,Christine Cheng,Theodore Nicolaides,Christopher S. Hackett,Zachary A. Knight,Kevan M. Shokat,William A. Weiss	160
18	Chemical-genetic inhibition of a sensitized mutant myosin Vb demonstrates a role in peripheral-pericentriolar membrane traffic 2004 ·Proceedings of the National Academy of Sciences ·David William Provance,(unknown),Colleen M. Silan,Luiz Cláudio Cameron,Kevan M. Shokat,James R. Goldenring,Kavita Shah,Peter G. Gillespie,John A. Mercer	33
19	Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations 2004 ·Proceedings of the National Academy of Sciences ·(unknown),J McLaughlin,(unknown),Cuilin Zhang,Kevan M. Shokat,Owen N. Witte	57
20	Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain 2003 ·Proceedings of the National Academy of Sciences ·(unknown),Eiji Shimizu,Ya‐Ping Tang,Min Cho,(unknown),(unknown),D Robinson,Peter J. Alaimo,Chao Zhang,Hiromi Morimoto,Min Zhuo,Ruiben Feng,Kevan M. Shokat,Joe Z. Tsien	126

About Kevan M. Shokat

Kevan M. Shokat is a scholar working on Molecular Biology, Cell Biology and Genetics, having authored 305 papers that have together received 34.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (68 papers), Protein Kinase Regulation and GTPase Signaling (46 papers) and Monoclonal and Polyclonal Antibodies Research (26 papers). The work is most often cited by research in Molecular Biology (24.3k citations), Cell Biology (5.4k citations) and Oncology (6.9k citations). Kevan M. Shokat has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Zachary A. Knight, J.M. Ostrem, Chao Zhang, Martin L. Sos, William A. Weiss, Ulf Peters, James A. Wells, Neal Rosen, Kavita Shah and Chao Zhang. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact